CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 165 enrolled
Drug / intervention
PNB Bupivacaine +4 moredrug
Likely dose
Epinephrine 100 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02242201
NCT02242201Phase 4Completed

Prospective, Randomized Controlled Trial Comparing Continuous Posterior Lumbar Plexus Nerve Block vs Periarticular Injection With Ropivacaine or Liposomal Bupivacaine (Exparel®) on Patients Undergoing Total Hip Arthroplasty

Mayo Clinic·interventional·Posted Sep 16, 2014·Updated Apr 19, 2018

In Brief

A Phase 4 clinical trial evaluating PNB Bupivacaine, PAI Ropivacaine, and 3 other interventions for Total Hip Arthroplasty. Completed, enrolled 165 participants across 1 site.

Detailed Summary

Total hip arthroplasty is a one of the most commonly performed surgical procedures with increasing numbers anticipated over the next several decades. The purpose of this study was to find a better way to make patients comfortable after their hip surgery. Three different ways of providing pain relief were compared, a peripheral nerve block in the lower back outside of the spinal space (using bupivacaine, a numbing medicine), or injections around the hip joint with one of two different medicines, either Ropivacaine or Liposomal Bupivacaine (Exparel®).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 16, 2014
Enrollment StartSep 1, 2014
Primary CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 11.8 years ago

Interventions

PNB Bupivacainedrug

Infusion

PAI Ropivacainedrug

Injection

PAI liposomal bupivacainedrug

Injection

Epinephrinedrug

Injection, weight-based dosage of 100 mcg - 300 mcg

Ketorolacdrug

Injection, 30 mg